Amneal Pharma buys Kashiv Specialty Pharma

Published On 2021-04-06 08:07 GMT | Update On 2021-04-06 08:07 GMT

Bridgewater: Amneal Pharmaceuticals, Inc. and Kashiv BioSciences LLC ("Kashiv") have recently announced that Amneal Pharmaceuticals LLC ("Amneal"), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.

"We are very pleased to announce the completion of this transaction. Through the acquisition of Kashiv Specialty Pharma, Amneal has gained an exciting pipeline of both 505(b)2 branded products and complex generics. Perhaps most importantly, we are adding a team of world class R&D scientists with a proven track record of developing complex generic products (e.g. Yuvafem and EluRyng), as well as a platform of innovative drug delivery technologies. This transaction is just the latest step in making Amneal 2.0 a reality," said Messrs. Chirag and Chintu Patel, Co-Chief Executive Officers.

Read also: Eloxx Pharma buys Zikani Therapeutics

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products.

The Company has an extensive portfolio of approximately 250 generic medicines and is expanding its portfolio to include complex dosage forms including biosimilars in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Amneal Pharma buys Kashiv Specialty Pharma

Similar News

CDSCO Tightens RTI Appeal Timelines, Division Heads to Face Penalties for Lapses

Patna HC Denies Bail in Codeine Syrup Case: Possession Below 2.5% Still NDPS Offence

Alembic Pharma Gets USFDA Nod for Generic Paxil CR Tablets

Game-Changer for HIV: Dr Reddy's, Hetero to Sell Generic Lenacapavir at Rs 3,547 a Year

Sanofi Commits USD 625 Million to Sanofi Ventures to Boost Biotech and Digital Health Startups

Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel

Zydus Lifesciences Gets CDSCO Panel Nod for Bioavailability Study of Antimalarial Candidate ZY-19489

Serum Institute, Vidal Health Partner for Digital Cashless HPV Vaccination Programme